Background: Since its inception in 1980, the MOHL index (% patients who are male, have occupational, hand, or leg dermatitis, respectively) and its later evolutions until the presently used MOAHLFA(P) index (adding % patients with atopic dermatitis, face dermatitis, age 40+ years and positive reaction(s) to ≥ 1 baseline series allergen) have been intended to convey important demographic and clinical information on the patients patch tested in a certain area and time, aiding the interpretation of the observed spectrum of sensitisation.

Objectives: To examine the current usage of the MOAHLFA(P) index and suggest consolidated definitions for its single items.

Methods: A title/abstract search in Medline identified publications mentioning the evolving acronyms. A Delphi-like survey among contact dermatitis experts collected agreement with suggested definitions.

Results: The search term 'MOAHLFA' was used in 35 publications from a broad geographical origin. More than 80% of the 24 participants of the survey (65% response) agreed on maintaining to use (i) sex for the 'M' criterion, (ii) occupation-related dermatitis irrespective of medicolegal definitions for the 'O', (iii) atopic dermatitis (but not rhinitis or asthma) for the 'A'. The possibility to use more than one site among 'H', 'L' and 'F' and a more detailed description of age distribution were favoured, and the difficult interpretability of the 'P' measure was highlighted.

Conclusions: The 'classical' MOAHLFA(P) index may be extended. Some aspects, notably atopic dermatitis, need further standardisation.

Download full-text PDF

Source
http://dx.doi.org/10.1111/cod.14750DOI Listing

Publication Analysis

Top Keywords

atopic dermatitis
12
dermatitis
7
'moahlfap index'
4
index' attempt
4
attempt standardise
4
standardise array
4
array descriptors
4
descriptors patch-tested
4
patients
4
patch-tested patients
4

Similar Publications

Background: Nemolizumab, a humanized monoclonal antibody against interleukin-31 receptor A (IL-31RA), is used to treat atopic dermatitis and prurigo nodularis. These inflammatory skin diseases affect a wide range of age groups, including pregnant women and children; however, little is known about their biological effects on pre- and postnatal development. Therefore, we report and discuss the results of an enhanced pre- and postnatal development study in cynomolgus monkeys treated with nemolizumab, which also incorporates an assessment of juvenile toxicities.

View Article and Find Full Text PDF

Alopecia areata (AA) is a chronic, autoimmune skin disease characterized by non-scarring hair loss. Baricitinib, a Janus kinase inhibitor (JAKi), prevents hair loss and promotes hair regrowth by inhibiting the inflammatory Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway involved in cytotoxic T cell responses targeting hair follicles. The introduction of JAKi has transformed treatment against severe AA.

View Article and Find Full Text PDF

Background: Itch is a common clinical sign in skin disorders. While the neural pathways of itch transmission from the skin to the brain are well understood in rodents, the same pathways in dogs remain unclear. The knowledge gap hinders the development of effective treatments for canine itch-related disorders.

View Article and Find Full Text PDF

Roads to remission: evolving treatment concepts in type 2 inflammatory diseases.

EClinicalMedicine

February 2025

Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Philipps University Marburg, Marburg, Germany.

Unlabelled: Non-communicable diseases (NCDs) characterised by type 2 inflammation, including asthma, allergic rhinitis, chronic rhinosinusitis with nasal polyps, atopic dermatitis, food allergies and eosinophilic esophagitis, are increasing in prevalence worldwide. Currently, there is a major paradigm shift in the management of these diseases, towards the concept of disease modification and the treatment goal remission, regardless of severity and age. Remission as a treatment goal in chronic inflammatory NCDs was first introduced in rheumatoid arthritis, and then adopted in other non-type 2 inflammatory diseases.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!